PriceTargets.com logo

NASDAQ:EIDX - Eidos Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $54.07
  • Forecasted Upside: -55.76 %
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 7 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$122.21 As of 01/26/2021 01:00 AM ET
+0.30 (1.20%)
Get New Eidos Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EIDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EIDX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$54.07
▼ -55.76% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Eidos Therapeutics in the last 3 months. The average price target is $54.07, with a high forecast of $73.26 and a low forecast of $34.00. The average price target represents a -55.76% upside from the last price of $122.21.
Hold
The current consensus among 9 polled investment analysts is to hold stock in Eidos Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
1/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
4/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
7/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
10/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
1/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
3/23/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
4/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 7 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/30/2020Smith Barney CitigroupReiterated RatingBuyN/A
i
11/18/2020BTIG ResearchDowngradeBuy ➝ NeutralLow
i
10/7/2020CitigroupDowngradeBuy ➝ Neutral$80.00 ➝ $73.26Medium
i
10/6/2020BMO Capital MarketsDowngradeOutperform ➝ Market PerformMedium
i
10/5/2020SVB LeerinkDowngradeOutperform ➝ Market PerformHigh
i
Rating by M. Foroohar at SVB Leerink LLC
10/5/2020Piper SandlerDowngradeOverweight ➝ NeutralHigh
i
9/22/2020GuggenheimDowngradeBuy ➝ NeutralHigh
i
9/8/2020CitigroupInitiated CoverageBuy$80.00High
i
5/14/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$58.00 ➝ $50.00Medium
i
5/11/2020BarclaysLower Price TargetUnderweight$45.00 ➝ $34.00High
i
Rating by Gena Wang at Barclays PLC
5/11/2020SVB LeerinkLower Price TargetOutperform$62.00 ➝ $59.00High
i
4/1/2020Bank of AmericaInitiated CoverageNeutral$51.00High
i
2/27/2020Piper SandlerBoost Price TargetOverweight$75.00 ➝ $80.00High
i
2/19/2020GuggenheimInitiated CoverageBuy$66.00High
i
2/18/2020BarclaysDowngradeEqual Weight ➝ Underweight$45.00Low
i
11/19/2019Piper Jaffray CompaniesBoost Price TargetOverweight$55.00 ➝ $75.00High
i
11/1/2019Roth CapitalBoost Price TargetBuy$51.00 ➝ $57.00Low
i
11/1/2019BarclaysDowngradeOverweight ➝ Equal Weight$37.00 ➝ $45.00High
i
10/15/2019BTIG ResearchSet Price TargetBuy$56.00High
i
Rating by Thomas Shrader at BTIG Research
9/13/2019BTIG ResearchSet Price TargetPositive ➝ Buy$56.00Medium
i
7/22/2019BMO Capital MarketsBoost Price TargetOutperform$50.00High
i
7/22/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$55.00High
i
5/8/2019BMO Capital MarketsBoost Price TargetOutperform$28.00 ➝ $40.00Medium
i
4/17/2019BTIG ResearchInitiated CoverageBuy$38.00Low
i
2/27/2019JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightHigh
i
2/22/2019BMO Capital MarketsInitiated CoverageOutperform$28.00High
i
1/23/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$29.00High
i
11/27/2018SVB LeerinkInitiated CoverageOutperform$32.00High
i
Rating by M. Foroohar at SVB Leerink LLC
10/31/2018Roth CapitalInitiated CoverageBuy$28.00High
i
Rating by Y. Rahimi at Roth Capital
10/1/2018Bank of AmericaLower Price TargetNeutral ➝ Neutral$24.00 ➝ $13.00High
i
7/16/2018Bank of AmericaInitiated CoverageNeutral$24.00High
i
7/16/2018JPMorgan Chase & Co.Initiated CoverageOverweight$36.00High
i
7/16/2018BarclaysInitiated CoverageOverweight$32.00High
i
(Data available from 4/22/2016 forward)
Eidos Therapeutics logo
Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.
Read More

Today's Range

Now: $122.21
$122.21
$122.21

50 Day Range

MA: $123.21
$120.98
$128.51

52 Week Range

Now: $122.21
$28.39
$132.54

Volume

N/A

Average Volume

128,113 shs

Market Capitalization

$4.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Eidos Therapeutics?

The following Wall Street analysts have issued research reports on Eidos Therapeutics in the last twelve months: Barclays PLC, BMO Capital Markets, BTIG Research, Citigroup Inc., Guggenheim, JPMorgan Chase & Co., Piper Sandler, Smith Barney Citigroup, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for EIDX.

What is the current price target for Eidos Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Eidos Therapeutics in the last year. Their average twelve-month price target is $54.07, suggesting a possible downside of 55.8%. Citigroup Inc. has the highest price target set, predicting EIDX will reach $73.26 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $34.00 for Eidos Therapeutics in the next year.
View the latest price targets for EIDX.

What is the current consensus analyst rating for Eidos Therapeutics?

Eidos Therapeutics currently has 1 sell rating, 7 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EIDX, but not buy more shares or sell existing shares.
View the latest ratings for EIDX.

What other companies compete with Eidos Therapeutics?

Other companies that are similar to Eidos Therapeutics include Catalent, Alnylam Pharmaceuticals, Elanco Animal Health, BioMarin Pharmaceutical, Zai Lab, Ono Pharmaceutical, Grifols, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries, Bausch Health Companies, Jazz Pharmaceuticals, United Therapeutics, Maravai LifeSciences, Mirati Therapeutics and BridgeBio Pharma.

How do I contact Eidos Therapeutics' investor relations team?

Eidos Therapeutics' physical mailing address is 101 MONTGOMERY STREET SUITE 2550, SAN FRANCISCO CA, 94104. The company's listed phone number is 415-887-1471 and its investor relations email address is [email protected] The official website for Eidos Therapeutics is www.eidostx.com.